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Background. The diagnosis of gambiense human African trypanosomiasis (gHAT) typically involves 2 steps: a serological 
screen, followed by the detection of living trypanosome parasites in the blood or lymph node aspirate. Live parasites can, however, 
remain undetected in some seropositive individuals, who, we hypothesize, are infected with Trypanosoma brucei gambiense parasites 
in their extravascular dermis.
Methods. To test this hypothesis, we conducted a prospective observational cohort study in the gHAT focus of Forecariah, 
Republic of Guinea. Of the 5417 subjects serologically screened for gHAT, 66 were enrolled into our study and underwent a derma-
tological examination. At enrollment, 11 seronegative, 8 unconfirmed seropositive, and 18 confirmed seropositive individuals had 
blood samples and skin biopsies taken and examined for trypanosomes by molecular and immunohistological methods.
Results. In seropositive individuals, dermatological symptoms were significantly more frequent, relative to seronegative con-
trols. T.b. gambiense parasites were present in the blood of all confirmed cases (n = 18) but not in unconfirmed seropositive individ-
uals (n = 8). However, T. brucei parasites were detected in the extravascular dermis of all unconfirmed seropositive individuals and 
all confirmed cases. Skin biopsies of all treated cases and most seropositive untreated individuals progressively became negative for 
trypanosomes 6 and 20 months later.
Conclusions. Our results highlight the skin as a potential reservoir for African trypanosomes, with implications for our understanding 
of this disease’s epidemiology in the context of its planned elimination and underlining the skin as a novel target for gHAT diagnostics.
Keywords.  skin; reservoir; human African trypanosomiasis; Trypanosoma brucei gambiense.
The number of new cases of gambiense human African trypan-
osomiasis (gHAT; or sleeping sickness) has never been so low 
in the known epidemiological history of the disease, with only 
~1500 new cases reported in 2017 [1, 2], and the World Health 
Organization (WHO) has targeted gHAT elimination by 2030 
[3]. This objective has been encouraged by the success of active 
surveillance efforts that relies on a 2-step diagnosis: an initial se-
rological screen, followed by microscope observation of blood, 
lymph, or cerebrospinal fluid (CSF) to detect extracellular tryp-
anosomes and to confirm the serological diagnosis. However, 
some seropositive individuals remain without a confirmed 
parasitological diagnosis for years and have been recently de-
scribed as being latent cases, raising the question as to whether 
reservoirs of live parasites persist in these individuals [4].
Trypanosoma brucei s.  l. parasites are found in the extra-
vascular compartment of various tissues of their mammalian 
hosts, including the skin, albeit mostly under experimental 
conditions in animal models rather than during the natural 
progression of the disease [5]. Recent studies have revealed 
that substantial quantities of trypanosomes persist within 
the extravascular dermis following experimental infection in 
mice with T.b. gambiense or T. b. brucei. These parasites can be 
transmitted to the tsetse vector, even in the absence of detect-
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retrospective screening of archived skin biopsies from a gHAT 
endemic region, which revealed the presence of some extravas-
cular skin-dwelling trypanosomes [6]. However, the species of 
these parasites was not identified and no clinical records were 
available for the screened samples.
These observations raise the question as to whether T.b. 
gambiense might be found in the skin of confirmed gHAT cases, 
as well as in unconfirmed seropositive individuals, in regions 
of active disease transmission. To address this question, we 
performed a prospective observational study in the Forecariah 
District in the Republic of Guinea, which is one of the most ac-
tive gHAT foci in Western Africa.
METHODS
More details for materials and methods are provided in the 
Supplementary Data.
Ethical Approval
All investigations were conducted in accordance with the 
Declaration of Helsinki and with the approval of the National 
Ethical Committee of the Republic of Guinea (Study Diag-Cut-
THA 032/CNERS/17 and amendment 038/CNERS/19).
Study Enrollment, Screening, and Case Definitions
From May 2017 to February 2019, a total of 5417 individuals were 
screened by the HAT National Control Programme using the 
card agglutination test for trypanosomiasis, first on whole-blood 
(CATTwb), then on plasma (CATTp) for validation, in 43 villages 
in the active gHAT focus of the Forecariah District, Republic of 
Guinea. All subjects were classified as seronegative, unconfirmed 
seropositive, or confirmed seropositive according to the diag-
nostic process presented in Table 1. All parasitologically confirmed 
cases were diagnosed and treated by the HAT National Control 
Programme according to WHO recommendations and as de-
scribed previously [7]. All confirmed cases (CATTp  ≥1/4 with 
parasitological confirmation) and all unconfirmed seropositive 
individuals (CATTp  ≥1/4 without parasitological confirmation) 
were proposed for study enrollment. In total, 40 seronegative con-
trols (39 CATTwb-negative and 1 CATTwb-positive CATTp <1/4) 
were randomly selected from the population of 5417, of whom the 
first 29 individuals, enrolled in 2017, were only included in the 
epidemiological and clinical analysis, and the last 11 individuals, 
enrolled in 2019, were subjected to the entire protocol. Children 
under 16 years of age and pregnant women were excluded from the 
study. Each participant was informed about the study’s objectives 
and provided written informed consent.
Field Procedure and Sampling
Participants underwent an epidemiological interview and 
a clinical examination, during which dermatological symp-
toms including pruritus (skin itch) and dermatitis (skin in-
flammation) were assessed at enrollment as well as at each 
subsequent follow-up at 6 and 20 months after enrollment/
treatment. Epidemiological and clinical parameters are de-
tailed in the Supplementary Data. The absence of dermatitis 
lesions at the skin sampling site was verified and a 2-mm 
blood-free skin punch biopsy was sampled from the right 
back shoulder of all confirmed seropositive cases, all uncon-
firmed seropositive individuals, and for the final 11 seroneg-
ative controls. Touch preparations were obtained by gently 
rolling the biopsy on a clean glass slide and Giemsa staining 
in the field. The positivity of a given slide was defined by 
the detection of at least 3 trypanosomes. Biopsies were fixed 
for immunohistochemistry (IHC) and molecular analyses. 
Plasma aliquots from blood samples were also obtained for 
serological trypanolysis tests [8].
Table 1. Diagnostic Process, Number of Subjects, and Results
Groups




Validation 3, Parasitological Confirmation 4, Staging No. of Subjects  
CATTwb / RDT CATTpa




No. WBCs in 
CSF Screened Enrolled Followed Up
Seronegative − ND ND ND 5377 40 0 
+ <1/4
Seropositive + ≥1/4 − ND 12 8 5 
Confirmed + ≥1/4 +      
 Stage 1 No 0–5 8 4 4 
 Stage 2 Yes >5 18 14 13 
 ND ND 2 0 0 
 All 28 18 17 
Total 5417 66 22 
Abbreviations: CATTp, card agglutination test for trypanosomiasis on plasma; CATTwb, card agglutination test for trypanosomiasis on whole blood; CSF, cerebrospinal fluid; mAECT BC/LN 
aspirate, mini anion-exchange column technique on buffy coat/lymph node aspirate; ND, not determined; WBC, white blood cell.
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Immunohistochemical Detection
Skin biopsy sections were stained with hematoxylin-eosin (H&E) 
and Giemsa stains, and immunolabelled with the T. brucei–spe-
cific anti-ISG65 antibody that targets the Invariant Surface 
Glycoprotein 65 expressed at the surface of the mammalian host 
stages of T. brucei s.l. parasites [9] and the T. brucei–specific anti-
Hsp70 antibody that recognizes the endoplasmic reticulum mo-
lecular chaperone heat-shock protein 70 homolog [10]. Slides were 
blindly assessed by at least 2 readers. Slides from seronegative con-
trols were mixed with slides from seropositive cases in order to 
guarantee blind reading. The positivity of a given skin-section slide 
was defined by the detection of at least 3 trypanosomes.
Polymerase Chain Reaction Detection
DNAs were extracted from paraffin-embedded biopsies and 
blood samples with tissue-specific commercial kits (Qiagen, 
Germany). For each sample, at least 2 polymerase chain reac-
tions (PCRs) were performed with T.  brucei-specific primers 
targeting a DNA satellite repeated sequence (10 000 copies per 
cell) [11], and T. brucei gambiense surface glycoprotein (TgsGP) 
primers directed against the single copy TgsGP gene [12], for 
detecting T. brucei s. l. and T.b. gambiense DNAs, respectively.
Data Analyses
For epidemiological, clinical, and diagnostic parameters, dif-
ferences between seronegative controls versus unconfirmed 
seropositive individuals and confirmed cases were assessed 
using the following 2-sided tests at 5% confidence: Fisher’s exact 
tests for qualitative data (Tables 2 and 3) and/or Mann-Whitney 
tests for quantitative data (age in Table  2). For the follow-up 
analyses, differences between results at enrolment versus results 
at 6 months and 20 months after treatment/enrollment were as-




Results of the initial screening of 5417 individuals are shown in 
Table 1. Out of 5377 seronegative subjects (CATTwb-negative 
or CATTp <1/4), 40 were enrolled as seronegative controls, of 
whom 11 provided skin biopsies. A total of 40 seropositive in-
dividuals (CATTwb-positive and CATTp ≥1/4) were identified 
during the survey, of whom 12 tested negative upon parasito-
logical examination (0.22%) and 28 were confirmed as HAT 
cases (0.52%). Eight nonconfirmed seropositive individuals and 
18 confirmed HAT cases had no exclusion criteria and accepted 
to be enrolled in the study.
As shown in Table 2, the occurrence of dermatitis was sig-
nificantly more frequent in confirmed HAT cases (15/18, 83%; 
P  <  .0001) and nonconfirmed seropositive individuals (5/8, 
63%; P = .0166) as compared with seronegative controls (7/40, 








Stage 1 (n = 4) Stage 2 (n = 14) All (n = 18) P
Epidemiologic        
 Age (n = 66), years 37.9 (14) 36.6 (18) .7647a 31.0 (17) 35.6 (15) 34.6 (15) .3502a
 Male sex (n = 66) 22/40 (55%) 3/8 (38%) .4538 2/4 (50%) 5/14 (36%) 7/18 (39%) .3950 
 HAT case(s) in the family since 2010 (n = 65) 11/40 (28%) 2/7 (29%) >.9999 2/4 (50%) 5/14 (36%) 7/18 (39%) .5404 
 Occupational risk (n = 66) 17/40 (43%) 4/8 (50%) .7155 2/4 (50%) 5/14 (36%) 7/18 (39%) >.9999 
Clinical        
 Swollen LNs (n = 65) 5/39 (13%) 6/8 (75%) .0010 4/4 (100%) 13/14 (93%) 17/18 (94%) <.0001 
 Any dermatological symptoms (n = 66) 8/40 (20%) 5/8 (63%) .0252 4/4 (100%) 13/14 (93%) 17/18 (94%) <.0001 
 Dermatitis (n = 66) 7/40 (18%) 5/8 (63%) .0166 4/4 (100%) 11/14 (79%) 15/18 (83%) <.0001 
 Pruritus (n = 66) 3/40 (8%) 2/8 (25%) .1887 0/4 (0%) 11/14 (79%) 11/18 (61%) <.0001 
 Asthenia (n = 65) 17/39 (44%) 4/8 (50%) >.9999 4/4 (100%) 14/14 (100%) 18/18 (100%) <.0001 
 Fever (n = 63) 6/38 (16%) 1/7 (14%) >.9999 2/4 (50%) 9/14 (64%) 11/18 (61%) .0013 
 Weight loss (n = 61) 6/39 (15%) 3/8 (38%) .1672 2/4 (50%) 6/10 (60%) 8/14 (57%) .0046 
 Eating disorders (n = 66) 4/40 (10%) 1/8 (13%) >.9999 0/4 (0%) 7/14 (50%) 7/18 (39%) .0250 
 Headache (n = 65) 23/39 (59%) 6/8 (75%) .6918 3/4 (75%) 13/14 (93%) 16/18 (89%) .0322 
 Circadian rhythm disruptions (n = 66) 3/40 (8%) 1/8 (13%) .5303 0/4 (0%) 5/14 (36%) 5/18 (28%) .0925 
 Sexual dysfunctions (n = 65) 4/39 (10%) 1/8 (13%) >.9999 0/4 (0%) 5/14 (36%) 5/18 (28%) .1236 
 Behavior changes (n = 63) 4/39 (10%) 0/7 (0%) >.9999 0/4 (0%) 3/13 (23%) 3/17 (18%) .6624 
Data are presented as n/total (%) or mean (SD). For each group and each parameter, total values correspond to the numbers of subjects for which a value was available (n/total). P values 
were obtained by comparing one by one the parameters of each group of seropositive subjects (unconfirmed and all confirmed) with those of seronegative controls using 2-sided Fisher’s 
exact tests or 2-sided Mann-Whitney tests at 5% confidence. 
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18%). Pruritus was the most frequent dermatological sign in 
patients with confirmed HAT (11/18, 61%), as compared with 
seronegative controls (3/40, 8%). Among the various observed 
clinical manifestations of localized dermatitis, we unambigu-
ously identified typical cases of intertrigo (in 4/18 confirmed 
cases vs 2/40 seronegative controls), pityriasis (in 3/18 vs 2/40), 
scabies (in 3/18 vs 1/40), dermatophytosis (in 3/18 vs 1/40), 
molluscum (in 3/18 vs 1/40), and ulceration (in 3/18 vs 1/40). 
The main clinical manifestations in nonconfirmed seropositive 
individuals were eczema (3/8), intertrigo (2/8), and pityriasis 
(1/8). Apart from general pruritus and intertrigo, all dermato-
logical signs were observed in upper regions of the body, espe-
cially on the thorax and arms.
Biological Results
Plasma from all confirmed and unconfirmed seropositive cases, 
and from 11 of 40 seronegative controls, was assessed using the 
trypanolysis test, which detects complement-mediated im-
mune responses activated by T.b. gambiense–specific antigens. 
All confirmed cases were positive for the LiTat 1.3 antigen, and 
89% (16/18) of these cases were positive for both the LiTat 1.5 
and 1.6 antigens (Table 3). Only 25% (2/8) of the unconfirmed 
seropositive individuals were positive for all antigens, while 
the others remained negative for all 3 variants, as seronegative 
controls.
A skin-punch biopsy was sampled from all enrolled con-
firmed and unconfirmed seropositive cases and from 11 of 40 
seronegative controls. Dermal touch preparations were then 
generated in the field and full-length trypanosomes were ob-
served on slides from 81% (13/16) of the confirmed cases and 
from 33% (2/6) of the unconfirmed seropositive individuals 
(Table  3, Supplementary Figure 1). One of the unconfirmed 
seropositive individuals who tested positive in this dermal test 
also tested positive in the trypanolysis test.
The skin biopsy samples were processed for IHC analyses 
in the laboratory. Skin samples obtained from the seronega-
tive controls (11/11) did not test positive for trypanosomes 
(Table 3). By contrast, all unconfirmed seropositive individ-
uals (8/8) and all confirmed cases (18/18) were found to be 
positive at least following staining by a T.  brucei–specific 
anti-ISG65 antibody (Figure  1, Supplementary Figure 2, 
Table  3). In addition, all samples from nonconfirmed sero-
positive individuals and confirmed cases were also found to 
be positive following either unspecific Giemsa staining and/
or unspecific H&E staining and/or labelling with a T. brucei–
specific anti-Hsp70 antibody (Figure  1, Supplementary 








Stage 1 (n = 4) Stage 2 (n = 14) All (n = 18) P
Trypanolysis        
 LiTat 1.3 positive (n = 36) 0/10 (0%) 2/8 (25%) .1830 4/4 (100%) 14/14 (100%) 18/18 (100%) <.0001
 LiTat 1.5 positive (n = 36) 0/10 (0%) 2/8 (25%) .1830 4/4 (100%) 12/14 (86%) 16/18 (89%) <.0001
 LiTat 1.6 positive (n = 36) 0/10 (0%) 2/8 (25%) .1830 4/4 (100%) 12/14 (86%) 16/18 (89%) <.0001
 Positive for all VATs (n = 36) 0/10 (0%) 2/8 (25%) .1830 4/4 (100%) 12/14 (86%) 16/18 (89%) <.0001
 Negative for all VATs (n = 36) 10/10 (100%) 6/8 (75%) .1830 0/4 (0%) 0/14 (0%) 0/18 (0%) <.0001
PCR on blood        
 TBR positive (n = 37) 0/11 (0%) 0/8 (0%) >.9999 4/4 (100%) 14/14 (100%) 18/18 (100%) <.0001
 TgsGP positive (n = 37) 0/11 (0%) 0/8 (0%) >.9999 2/4 (50%) 10/14 (71%) 12/18 (67%) .0004
 Negative for all PCRs on blood (n = 37) 11/11 (100%) 8/8 (100%) >.9999 0/4 (0%) 0/14 (0%) 0/18 (0%) <.0001
PCR on skin        
 TBR positive (n = 37) 0/11 (0%) 6/8 (75%) .0010 1/4 (25%) 13/14 (93%) 14/18 (78%) <.0001
 TgsGP positive (n = 37) 0/11 (0%) 0/8 (0%) >.9999 0/4 (0%) 0/14 (0%) 0/18 (0%) >.9999
 Negative for all PCRs on skin (n = 37) 11/11 (100%) 2/8 (25%) .0010 3/4 (75%) 1/14 (7%) 4/18 (22%) <.0001
Histology        
 Dermal touchpreps (n = 22, 3 reads) ND 2/6 (33%)  1/3 (33%) 12/13 (92%) 13/16 (81%)  
 H&E section (n = 36, 1 read) 0/11 (0%) 6/8 (75%) .0010 4/4 (100%) 8/13 (62%) 12/17 (71%) .0003
 Giemsa section (n = 37, 2 reads) 0/11 (0%) 4/8 (50%) .0181 0/4 (0%) 14/14 (100%) 14/18 (78%) <.0001
 IHC Hsp70 (n = 31, 1 read) 0/11 (0%) 1/4 (25%) .2667 1/4 (25%) 11/12 (92%) 12/16 (75%) .0002
 IHC ISG65 (n = 37, 3 reads) 0/11 (0%) 8/8 (100%) <.0001 4/4 (100%) 14/14 (100%) 18/18 (100%) <.0001
 Negative for all reads (n = 37) 11/11 (100%) 0/8 (0%) <.0001 0/4 (0%) 0/17 (0%) 0/18 (0%) <.0001
Data are presented as n/total (%). For each group and each parameter, total values correspond to the numbers of subjects for which a value was available (n/total). P values were obtained 
by comparing one by one the parameters of each group of seropositive subjects (unconfirmed and all confirmed) with those of seronegative controls using 2-sided Fisher’s exact tests at 
5% confidence. 
Abbreviations: H&E, hematoxylin-eosin; Hsp70, heat shock protein 70; IHC, immunohistochemistry; ISG65, invariant surface glycoprotein 65; PCR, polymerase chain reaction; TBR, 
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Figure 2, Table 3). In positive skin sections, T. brucei para-
sites were evenly distributed in the reticular dermis, and were 
occasionally associated with edema. No other parasites were 
detected in any of the skin samples.
To confirm the identity of these skin-dwelling parasites, 
T.  brucei–specific PCR (TBR-PCR) assays were performed 
on total DNA extracted from fresh blood and from paraffin-
embedded skin samples. Both blood and skin DNA samples 
from the seronegative controls (11/11) were found to be neg-
ative by the TBR-PCR assays. By contrast, 100% of blood 
(18/18) and 78% of skin samples (14/18) from confirmed 
cases tested positively in the TBR-PCR assays. Parasite DNA 
was only detected in the skin of unconfirmed seropositive 
individuals (6/8, 75%) but not in their blood (0/8) (Table 3). 
T.b. gambiense–specific TgsGP-PCR assays were performed 
on the same DNA samples and were positive for only 67% 
(12/18) of the blood samples of confirmed cases (Table 3). We 
reasoned that the use of fresh skin biopsies would be more 
appropriate than paraffin-embedded skin samples for TgsGP-
PCR due to the low sensitivity of this method targeting a sin-
gle-copy gene. To test this hypothesis, we obtained fresh skin 
samples from an outgroup of 9 additional confirmed cases, 
who were identified in 2018 in the same district by using the 
same study protocol (Supplementary Table 1). The fresh skin 
samples from 89% (8/9) of these confirmed cases were found 
to be positive to TBR-PCR, and 33% (3/9) were also found to 
be positive to TgsGP-PCR (Supplementary Table 1).
Follow-up Results
The same panels of analyses were repeated at 6 and 20 months 
after study enrollment of the unconfirmed seropositive indi-
viduals or after treatment of the confirmed cases (Table 4). In 
total, 17 of 18 and 12 of 18 confirmed cases were followed up 
at 6 months and 20 months after treatment, respectively, with 
12 of 18 confirmed cases followed up twice, 5 of 18 followed 
up once, and 1 lost to follow-up (Table 4). Most of the clinical 
symptoms associated with the stage 2 cases at enrollment, in-
cluding dermatological signs, significantly decreased in fre-
quency during the first 6 months after treatment. Although all 
parasitological observations and PCR results became negative 
within 6 months after treatment in all confirmed cases (17/17), 
trypanosomes were still detected by histological methods in up 
to 38% of them (5/13 by IHC anti-ISG65). Twenty months after 
treatment, all CATTp and histological tests became negative 
(12/12), with 2 of 3 confirmed cases remaining positive to the 
trypanolysis test (Table 4).
In total, 5 of 8 and 4 of 8 unconfirmed seropositive individuals 
were followed up at 6 months and 20 months after enrollment, 
respectively, with 4 of 8 unconfirmed seropositive individuals 
followed up twice, 1 of 8 followed-up once, and 3 of 8 lost to 
follow-up (1 death, 1 pregnancy, and 1 resignation) (Table 4). In 
80% (4/5) of the unconfirmed seropositive individuals who were 
monitored after enrollment, dermatological signs progressively 
disappeared (Table 4). The 4 unconfirmed seropositive individ-
uals whose trypanolysis test was negative at enrollment became 
negative to CATTp, TBR-PCR on skin, and IHC anti-ISG65 in 
the same period. In contrast, the only trypanolysis-positive in-
dividual who could be monitored at 6 months maintained a se-
rological reactivity to CATTp. No parasite DNA was detected by 
TBR-PCR in either blood or skin, but the skin biopsy remained 
positive by IHC-ISG65. Although this individual was lost to fol-
low-up at the 20-month time point, he was diagnosed as a stage 
1 case (CATTp 1/8, mAECT-BC+, CSF−, and WBC 4 : 4 white 
blood cells counted in the LCR) during an active surveillance 
campaign that was led in November 2019 (ie, after the end of 
this study) and was treated accordingly.
Figure 1.  Extravascular trypanosomes in the dermal matrix of human skin biopsies. For each enrolled study subject, paraffin-embedded skin biopsy sections were stained 
either with a specific anti-ISG65 antibody (brown) (A) or with Giemsa (purple) (B) and screened at 100× magnification. Representative trypanosome sections from confirmed 
stage 1 (subject 1044) and stage 2 cases (subjects 1035, 1036, 1037, 1039, and 1042), as well as from unconfirmed seropositive individuals (subjects 1046, 1065, and 1066), 
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DISCUSSION
Here, we set out to investigate whether T.b. gambiense para-
sites might be found in the skin of confirmed gHAT cases, as 
well as in unconfirmed seropositive individuals, in regions of 
active disease transmission. Although this study is somewhat 
limited to a restricted population and to the detection methods 
used, 100% of the confirmed cases and unconfirmed seropos-
itive subjects were found to carry extravascular trypanosomes 
in their skin.
Dermatological Signs in gambiense Human African Trypanosomiasis
Our results indicate that dermatological symptoms might be an 
important aspect of gHAT’s clinical presentation. The few re-
ports that exist on this topic in the literature describe a wide 
array of skin pathologies associated with sleeping sickness, in-
cluding pruritus, chancre, rashes, and localized edemas [13, 14]. 
However, detailed dermatological profiles of HAT cases have 
mostly been derived from light-skinned travelers with imported 
HAT [14]. Whereas chancres and rashes remain anecdotal, pru-
ritus was the most commonly observed dermatological sign in 
endemic cases (in up to 57% of stage 2 cases) [14]. Here, we 
observed a higher occurrence of pruritus and dermatitis in un-
confirmed seropositive individuals and in confirmed cases rela-
tive to seronegative controls (Table 2). The observed dermatitis 
profiles included some conditions the etiologies of which might 
not be directly related to a trypanosome infection. However, it 
could be hypothesized that the immune status of the infected 
host skin is somehow altered by the presence of trypanosomes 
in a way that promotes the outcome of dermatitis caused by 
other pathogens and/or increases skin sensitivity.
Trypanosome Detection
The direct detection of trypanosomes in the human skin is not 
well documented in the literature [13]. As there is no gold-
standard approach for that purpose, we implemented 7 distinct 
molecular and immunohistological methods in parallel, yet 
with their own specific strengths and weaknesses. Here, dermal 
touch preparations were generated in the field in suboptimal 
ambient conditions (31°C at 75% humidity, on average), which 
could explain the unusual morphology of some trypanosomes, 
which were probably altered by osmotic shock while drying. 
Then, only a limited portion of each parasite is visible in the 
2.5-μm skin sections because entire trypanosomes do not nec-
essarily lie in the section plan. For the same reason, the parasite 
nucleus, kinetoplast, and flagellum are rarely all visible in the 
same given cell section. However, the specificities of the anti-
ISG65 and anti-Hsp70 antibodies enable to unambiguously 
detect most T. brucei parasites within the extracellular dermal 
matrix, and this is confirmed by TBR-PCR assays. Considering 
that T.b. brucei are noninfectious to humans and killed within a 
couple of hours by human serum, the dermal parasites detected 
here, at least in confirmed cases, are likely to be T.b. gambiense 
parasites, as confirmed by the positivity of some direct TgsGP-
PCR assays performed on fresh skin samples from an outgroup. 
However, further genetic studies would be necessary to rule out 
the hypothesis of infections with a peculiar T.b. brucei strain.
The detection of skin-dwelling parasites at enrollment in 
most of the 2-mm skin-punch biopsies sampled from seropos-
itive individuals indicates that skin-dwelling parasites might 
be present over a considerable proportion of the skin surface. 
However, the precise dynamics of parasite load and distribution 
in the extravascular dermal compartment over the course of an 
infection remain unknown. According to historic (reviewed in 
[5]) and more recent [6] studies in experimental animal models, 
skin-dwelling parasites could theoretically be detected in al-
most the entire skin surface, yet with a variable distribution and 
at variable local densities.
A Dermal Reservoir of Trypanosomes in Nonconfirmed Seropositive 
Individuals
One possible explanation for the persistence of disease foci in 
certain regions is the presence of animal reservoirs [15]. Another 
possibility, as increasing evidence suggests, is that traditionally 
used diagnostic approaches do not detect some T.b. gambiense 
infections among seropositive cases [15]. Indeed, bloodstream 
parasite numbers in T.b. gambiense infections can periodically 
fluctuate to less than 100 trypanosomes/mL, falling below the 
detection limit of the most sensitive methods currently in use 
[16]. Another study estimated that 20–30% of gHAT cases are 
missed in active case detection by standard parasitological tech-
niques and are left untreated [17]. These infected individuals 
might ultimately progress to clinical disease or remain almost 
asymptomatic until undergoing a possible self-cure [15].
Here, routine molecular analyses confirmed the presence 
of T.  brucei parasites in the skin of unconfirmed seropositive 
individuals, including those testing negative to the LiTat 1.3 
trypanolysis test known to be highly specific of T.b. gambiense. 
As previously observed in the same transmission focus [7], 
trypanolysis-negative individuals rapidly became negative to 
CATTp and this was associated with the disappearance of de-
tectable dermal trypanosomes. In such subjects, dermal infec-
tions could be transient and too short to allow T.b. gambiense 
to invade the bloodstream and express the LiTat 1.3 antigen. 
Alternatively, these infections could possibly be caused by other 
trypanosome species cross-reacting with the CATT. More sen-
sitive and extensive molecular analyses will be required to solve 
this question.
Only 2 unconfirmed seropositive individuals were positive 
to the LiTat 1.3 trypanolysis test in this study. One died be-
fore the first follow-up and the other was lost to follow-up 
after 6  months. Nevertheless, it is noteworthy that this last 
individual, who was still positive to histological tests at 
6 months, was eventually diagnosed as a stage 1 case during a 
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characterization and follow-up of dermal trypanosomes in 
unconfirmed seropositive individuals testing positive to the 
LiTat 1.3 trypanolysis test would be required to better ad-
dress the role of these individuals in the transmission of T.b. 
gambiense.
Transmission and Epidemiological Contribution of Dermal Trypanosomes
Mathematical modeling recently predicted that, in the ab-
sence of any animal reservoirs, these unconfirmed seropos-
itive individuals could contribute to disease transmission by 
maintaining an overlooked reservoir of skin-dwelling para-
sites [18]. The infected skin of seropositive unconfirmed indi-
viduals could provide a population of parasites that are readily 
accessible to the tsetse fly. Indeed, this mode of transmission 
has been demonstrated in experimental animal models, in 
which skin-dwelling trypanosomes were efficiently trans-
mitted to the tsetse vector, even in the absence of detectable 
parasitemia [6, 19, 20]. However, the presence of the stumpy 
parasite forms that are assumed to be most adapted for de-
velopment in tsetse flies was not investigated here. This is 
an important question for future studies to address in order 
to estimate the actual infectivity potential of human skin–
dwelling parasites. Our reported observations should also be 
confirmed in a larger number of unconfirmed seropositive 
individuals (including Rapid Diagnostic Test (RDT)-positive 
subjects), and the study scaled up to include other endemic 
transmission foci in Africa, in order to confidently determine 
the actual prevalence of dermal trypanosomes.
Our results raise questions about the strategies used to diag-
nose this disease, which currently focus on detecting parasites 
in the blood and lymph. If the human skin is indeed a reservoir 
for trypanosomes, it could represent a novel target for diag-
nostics, and it could (1) allow more carriers to be treated, (2) 
help to determine a more accurate estimate of the true prev-
alence of the disease, and (3) help identify as yet undetected 
reservoirs in both human and animal populations. The devel-
opment of less invasive and field-adapted diagnostic methods 
to detect extravascular dermal trypanosomes, such as the se-
rological detection of skin-related biomarkers or the identifi-
cation of specific biophysical profiles by skin scanning, would 
benefit these goals. The current WHO recommendation, based 
on risk–benefit analyses, is to not treat unconfirmed sero-
positive individuals without knowing if they have an active 
infection [1]. Importantly, we observed that the routinely ad-
ministered trypanocide treatments (pentamidine for stage 1 
and Nifurtimox-Eflornithine Combination Therapy (NECT) 
for stage 2 cases) efficiently targeted both bloodstream and 
dermal trypanosomes in all of the patients followed up over 
20 months. With the promise of new, cheaper, less toxic, and 
easier to administer drugs on the horizon, the policy of treating 
unconfirmed seropositive individuals could possibly be recon-
sidered. Indeed, the new drug Acoziborole (SCYX-7158, Anacor 
Pharmaceuticals), which requires a single oral administra-
tion, could be the next revolutionary treatment against gHAT. 
As gHAT approaches its elimination targets, we propose from 
our findings that the current algorithms, used to identify and 
manage disease cases, could be adapted to include the detection 
of skin-dwelling parasites, which likely represent a previously 
unaccounted for anatomical reservoir.
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